Page last updated: 2024-11-05

ticlopidine and Coronary Occlusion

ticlopidine has been researched along with Coronary Occlusion in 14 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Coronary Occlusion: Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.

Research Excerpts

ExcerptRelevanceReference
" No data exist about the impact of HRPR after 600 mg clopidogrel loading on long-term clinical outcome in patients with diabetes mellitus and treated with percutaneous coronary angioplasty (PCI) for chronic total occlusion (CTO)."3.81Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. ( Abbate, R; Antoniucci, D; Cantini, G; Carrabba, N; Cerisano, G; Comito, V; Gensini, GF; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Parodi, G; Valenti, R; Vergara, R, 2015)
"CABG had similar rates of cardiac death compared with PCI group (HR=0."1.42Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication. ( Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, WJ; Kim, BS; Kim, WS; Lee, SH; Lee, YT; Song, YB; Yang, JH, 2015)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's12 (85.71)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Parker, WA1
Bhatt, DL1
Prats, J1
Day, JRS1
Steg, PG1
Stone, GW1
Hamm, CW1
Mahaffey, KW1
Price, MJ1
Gibson, CM1
White, HD1
Storey, RF1
Martin, J1
Williams, AK1
Klein, MD1
Sriramoju, VB1
Madan, S1
Rossi, JS1
Clarke, M1
Cicci, JD1
Cavallari, LH1
Weck, KE1
Stouffer, GA1
Lee, CR1
Sorich, MJ1
Rowland, A1
McKinnon, RA1
Wiese, MD1
Kim, BS1
Yang, JH1
Jang, WJ1
Song, YB1
Hahn, JY1
Choi, JH1
Kim, WS1
Lee, YT1
Gwon, HC1
Lee, SH1
Choi, SH1
Valenti, R1
Cantini, G1
Marcucci, R1
Marrani, M1
Migliorini, A1
Carrabba, N1
Comito, V1
Vergara, R1
Cerisano, G1
Parodi, G1
Abbate, R1
Gori, AM1
Gensini, GF1
Antoniucci, D1
Shaukat, A1
Al-Bustami, M1
Ong, PJ1
Jang, SW1
Kim, DB1
Kwon, BJ1
Shin, D1
Her, SH1
Park, CS1
Park, HJ1
Park, MW1
Cho, EJ1
Rho, TH1
Kim, JH1
Dixon, SR1
Grines, CL1
O'Neill, WW1
Barison, A1
de Carlo, M1
Bellini, F1
Capozza, PF1
Lunardini, A1
Petronio, AS1
Martín-Yuste, V1
Alvarez-Contreras, L1
Cola, C1
Brugaletta, S1
García Picart, J1
Martí, V1
Masotti, M1
Sabaté, M1
Yan, BP1
Ajani, AE1
Clark, DJ1
Duffy, SJ1
Andrianopoulos, N1
Brennan, AL1
Loane, P1
Reid, CM1
Hondo, T1
Matsumura, H1
Matsuda, K1
Iwamoto, A1
Eno, S1
Kimura, M1
Mannacio, VA1
Di Tommaso, L1
Antignan, A1
De Amicis, V1
Vosa, C1
Elefteriades, JA1
Meier, P1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]Phase 311,145 participants (Actual)Interventional2010-09-30Completed
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00305162]Phase 38,882 participants (Actual)Interventional2006-04-30Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00385138]Phase 35,364 participants (Actual)Interventional2006-09-30Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand[NCT01301625]78 participants (Actual)Observational2011-11-30Terminated (stopped due to As recruitment rate was lower than anticipated)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Treatment Arm257
Clopidogrel Treatment Arm322

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
GUSTO severe/life threateningGUSTO moderateGUSTO severe or moderateTIMI majorTIMI minorTIMI major or minorAny blood transfusion
Cangrelor Treatment Arm92231591425
Clopidogrel Treatment Arm6131953816

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
Stent ThrombosisDeathMI (myocardial infarction)IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm461820728
Clopidogrel Treatment Arm741825538

Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI

(a patient could have multiple procedural events) (NCT00305162)
Timeframe: during index PCI

Interventionparticipants (Number)
Cangrelor Arm127
Clopidogrel Arm141

Incidence of ACUITY Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm151
Clopidogrel Arm120

Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)

excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm78
Clopidogrel Arm65

Incidence of All Cause Mortality

(excluding STEMI) (NCT00305162)
Timeframe: randomization through 1 year after randomization

Interventionparticipants (Number)
Cangrelor Arm116
Clopidogrel Arm120

Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm34
Clopidogrel Arm29

Incidence of All-cause Mortality and MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm285
Clopidogrel Arm261

Incidence of All-cause Mortality or MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm321
Clopidogrel Arm298

Incidence of All-cause Mortality, MI or IDR

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm343
Clopidogrel Arm327

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm290
Clopidogrel Arm276

Incidence of GUSTO Severe / Life-threatening Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm10
Clopidogrel Arm11

Incidence of IDR

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm44
Clopidogrel Arm52

Incidence of MI

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm297
Clopidogrel Arm276

Incidence of Stroke

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm5
Clopidogrel Arm7

Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm19
Clopidogrel Arm14

Individual Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm8
Clopidogrel Arm5

Individual Incidence of IDR

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm13
Clopidogrel Arm23

Incidence of Stroke

"Stroke is defined as a sudden, focal neurological defect resulting from a cerebrovascular cause that is not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or trauma. All suspected strokes were reviewed and adjudicated by the Clinical Events Committee (CEC) who considered all clinically relevant information and imaging studies to classify all strokes as:~primary hemorrhagic - stroke with focal collections of intracranial blood~ischemic cerebral infarction - stroke without focal collections of intracranial blood~infarction with hemorrhagic conversion - cerebral infarction with blood thought to represent hemorrhagic conversion and not primary bleeding~uncertain - no imaging or autopsy data are available." (NCT00305162)
Timeframe: randomization through 48 hours after randomization

,
Interventionparticipants (Number)
primary hemorrhagicinfarction with hemorrhagic conversioncerebral infarctionuncertain type
Cangrelor Arm1050
Clopidogrel Arm0070

Incidence of ACUITY Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor145
Clopidogrel91

Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm

Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm. (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor43
Clopidogrel29

Incidence of All-cause Mortality

mITT population (NCT00385138)
Timeframe: randomization through 1 year post randomization

Interventionparticipants (Number)
Cangrelor94
Clopidogrel113

Incidence of All-cause Mortality

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor35
Clopidogrel45

Incidence of All-cause Mortality

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor6
Clopidogrel18

Incidence of All-cause Mortality or MI

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor213
Clopidogrel233

Incidence of All-cause Mortality or MI

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor180
Clopidogrel204

Incidence of All-cause Mortality, MI, or IDR

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor227
Clopidogrel249

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)

mITT population; (composite incidence) (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor185
Clopidogrel210

Incidence of GUSTO Severe / Life-threatening

Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor9
Clopidogrel6

Incidence of IDR

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor37
Clopidogrel46

Incidence of IDR

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor19
Clopidogrel24

Incidence of MI

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor189
Clopidogrel201

Incidence of MI

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor177
Clopidogrel191

Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]

mITT population A patient could have multiple procedural events. (NCT00385138)
Timeframe: During index PCI

Interventionparticipants (Number)
Cangrelor122
Clopidogrel142

Incidence of Stent Thrombosis

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor15
Clopidogrel28

Incidence of Stent Thrombosis

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor5
Clopidogrel16

Incidence of Stroke

mITT (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor7
Clopidogrel5

Incidence of Stroke

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor6
Clopidogrel5

Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major

Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor4
Clopidogrel9

Device Time

This is one of the Device and Procedure-Related Endpoints. Device Time is defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter. Device Time is shorter in duration than Procedure Time because it does not include the time required to perform transseptal access into the left atrium. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant91.2

Fluoroscopy Duration

This is one of the Device and Procedure-Related Endpoints. Mean fluoroscopy duration during the MitraClip procedure. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant41.2

Number of Participants With Acute Procedural Success Rate

Defined as successful MitraClip implantation with resulting MR of 2+ or less. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionParticipants (Count of Participants)
MitraClip Implant39

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
MitraClip Implant8.3

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
MitraClip Implant0.0

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
MitraClip Implant6.1

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
MitraClip Implant0.0

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded. B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
MitraClip Implant91.5

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
MitraClip Implant85.3

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
MitraClip Implant96.1

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
MitraClip Implant100

Post-procedure Hospital Stay

This is the Economic data reported to support the MitraClip System economic analysis. It is defined as the mean duration of time that patients spent in hospital following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

InterventionDays (Mean)
MitraClip Implant3.4

Post-procedure Intensive Care Unit (ICU)/Critical Care Unit (CCU)/Post-anesthesia Care Unit (PACU) Duration

ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

InterventionHours (Mean)
MitraClip Implant62.1

Procedure Time

This is one of the Device and Procedure-Related Endpoints. Procedure Time is defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant133.5

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 12 months

InterventionMeters (Mean)
MitraClip Implant329.9

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 30 days

InterventionMeters (Mean)
MitraClip Implant297.3

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 6 months

InterventionMeters (Mean)
MitraClip Implant324.3

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: Baseline

InterventionMeters (Mean)
MitraClip Implant271.0

Total Contrast Volume

This is one of the Device and Procedure-Related Endpoints. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMilliliters (Mean)
MitraClip Implant10.6

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 12 Months

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 12 months

Interventionscores on a scale (Mean)
Baseline12 monthsDifference (12 months - Baseline)
MitraClip Implant51.130.2-20.9

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 30 Days

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 30 days

Interventionscores on a scale (Mean)
Baseline30 daysDifference (30 days - Baseline)
MitraClip Implant50.426.4-24.0

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 6 Months

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 6 months

Interventionscores on a scale (Mean)
Baseline6 monthsDifference (6 months - Baseline)
MitraClip Implant49.528.0-21.5

Duration of Rehospitalization

(NCT01301625)
Timeframe: 30 days

InterventionDays (Mean)
All re-hospitalizationsHeart Failure-related re-hospitalizationsOther cardiac-related re-hospitalizationsOther non-cardiac-related re-hospitalizations
MitraClip Implant8.418.382.877.44

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant148.5132.4

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant140.4138.8

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionml (Mean)
BaselineDischarge
MitraClip Implant141.7141.8

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant161.1150.1

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant152.9148.2

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionMilliliters (Mean)
BaselineDischarge
MitraClip Implant158.2151.3

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionpercent (Mean)
Baseline12 Months
MitraClip Implant46.947.4

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionpercent (Mean)
Baseline30 Days
MitraClip Implant48.446.5

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionpercent (Mean)
BaselineDischarge
MitraClip Implant47.244.6

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant97.891.7

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant88.589.0

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionMilliliter (Mean)
BaselineDischarge
MitraClip Implant93.393.2

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm (Mean)
Baseline12 Months
MitraClip Implant6.05.7

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm (Mean)
Baseline30 Days
MitraClip Implant5.95.7

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm (Mean)
BaselineDischarge
MitraClip Implant5.95.7

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm (Mean)
Baseline12 Months
MitraClip Implant4.64.5

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm (Mean)
Baseline30 Days
MitraClip Implant4.54.5

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm (Mean)
BaselineDischarge
MitraClip Implant4.54.4

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm^2 (Mean)
Baseline12 Months
MitraClip Implant3.82.3

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm^2 (Mean)
Baseline30 Days
MitraClip Implant3.52.3

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm^2 (Mean)
BaselineDischarge
MitraClip Implant3.52.4

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 12 Months

InterventionmmHg (Mean)
Baseline12 Months
MitraClip Implant2.33.4

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 30 Days

InterventionmmHg (Mean)
Baseline30 Days
MitraClip Implant2.33.5

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionmmHg (Mean)
BaselineDischarge
MitraClip Implant2.33.7

Number of Participants at Discharge Facility

This is the economic data reported to support the MitraClip System economic analysis. (NCT01301625)
Timeframe: < or = 12 days

InterventionParticipants (Count of Participants)
HomeHome with home health careSkilled nursing facilityNursing homeDeathOther
MitraClip Implant7041021

Number of Participants With 0, 1, 2, and 3 MitraClip Devices Implanted

This is one of the Device and Procedure-Related Endpoints. Implant Rate is defined as the rate of successful delivery and deployment of MitraClip device implant(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter. (NCT01301625)
Timeframe: Day 0 (On the day of procedure)

InterventionParticipants (Count of Participants)
0 Mitra Clip devices1 Mitra Clip devices2 Mitra Clip devices3 Mitra Clip devices
MitraClip Implant141351

Number of Participants With Mitral Valve Surgery

Mital Valve Surgery Post-MitraClip Procedure; Surgery Types includes Replacement and Repair. (NCT01301625)
Timeframe: 30 days of Post-MitraClip Procedure

InterventionParticipants (Count of Participants)
Recurring mitral regurgitationDevice failure
MitraClip Implant11

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant21515730

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant126251250

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant020241240

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: At discharge (≤7 days of index procedure)

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant13822931

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: Baseline

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant00022550

Number of Participants With Second Intervention to Place an Additional MitraClip Device

Second MitraClip device interventions are reported by Abbott Vascular personnel on Procedural Observation Forms. A second MitraClip device intervention is a good option for patients with MR following placement of the original MitraClip device. (NCT01301625)
Timeframe: Through 12 months

InterventionParticipants (Count of Participants)
Recurring mitral regurgitationSingle leaflet device attachment (SLDA)
MitraClip Implant21

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant52.542.52.52.5

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant36.244.915.92.9

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant33.356.78.31.7

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant2.626.951.319.2

Rate of Patients Rehospitalized

Defined as re-admission of patients to the hospital following discharge from the Clip procedure. (NCT01301625)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
All re-hospitalizationsHeart Failure-related re-hospitalizationsOther cardiac-related re-hospitalizationsOther non-cardiac-related re-hospitalizations
MitraClip Implant35101122

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 12 Months

InterventionPercentage (Mean)
Baseline12 Months
MitraClip Implant44.636.8

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 30 Days

InterventionPercentage (Mean)
Baseline30 Days
MitraClip Implant40.515.2

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionPercentage (Mean)
BaselineDischarge
MitraClip Implant38.925.8

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant49.873.3

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant61.925.6

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionml (Mean)
BaselineDischarge
MitraClip Implant55.525.1

Reviews

2 reviews available for ticlopidine and Coronary Occlusion

ArticleYear
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
    Circulation. Cardiovascular genetics, 2014, Volume: 7, Issue:6

    Topics: Alleles; Asian People; Clopidogrel; Coronary Occlusion; Cytochrome P-450 CYP2C19; Databases, Factual

2014
The year in interventional cardiology.
    Journal of the American College of Cardiology, 2010, May-18, Volume: 55, Issue:20

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp

2010

Trials

2 trials available for ticlopidine and Coronary Occlusion

ArticleYear
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:23

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass, Off-Pum

2012

Other Studies

10 other studies available for ticlopidine and Coronary Occlusion

ArticleYear
Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
    Genetics in medicine : official journal of the American College of Medical Genetics, 2020, Volume: 22, Issue:1

    Topics: Aged; Clopidogrel; Coronary Occlusion; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Mid

2020
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
    International journal of cardiology, 2015, Oct-15, Volume: 197

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass;

2015
Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus.
    International journal of cardiology, 2015, Dec-15, Volume: 201

    Topics: Aged; Blood Platelets; Chronic Disease; Clopidogrel; Coronary Occlusion; Diabetes Mellitus; Dose-Res

2015
Chronic total occlusion--use of a 5 French guiding catheter in a 6 French guiding catheter.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Occlusion; Coronary Restenosis; Coronary

2008
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
    International journal of cardiology, 2010, Apr-01, Volume: 140, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occ

2010
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
    Acute cardiac care, 2011, Volume: 13, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug

2011
[Usefulness of the Tornus® catheter in nondilatable coronary chronic total occlusion].
    Revista espanola de cardiologia, 2011, Volume: 64, Issue:10

    Topics: Aged; Cardiac Catheterization; Catheterization; Catheters; Clopidogrel; Coronary Angiography; Corona

2011
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
    The Medical journal of Australia, 2011, Aug-01, Volume: 195, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb

2011
A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:6

    Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Aspirin; Autoantibodies

2012
Clopidogrel and cardiac surgery: enemy or friend?
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:23

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Occlusion;

2012